^
BIOMARKER:

FGFR3 expression

i
Other names: FGFR3, ACH, CD333, CEK2, JTK4, Fibroblast growth factor receptor 3
Entrez ID:
25d
Single Cell Multi-Omic Profiling of Multiple Myeloma with t(4;14) Finds an Immune Microenvironment Gene Signature That Correlates with Clinical Outcomes (ASH 2021)
We first analyzed serial BM samples from an individual patient that were taken at diagnosis and relapse following bortezomib based treatment...In addition, we identified a gene signature expressed in a rare population of non-plasma cells that significantly correlated with PFS in this patient cohort. These data highlight the potential of single cell multi-omic analysis to identify immune micro-environmental signatures that correlate with response to therapy in t(4;14) MM.
Clinical • Clinical data • Gene Signature
|
FGFR3 (Fibroblast growth factor receptor 3) • CD14 • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SDC1 (Syndecan 1) • H2BC8 (H2B Clustered Histone 8)
|
Chr t(4;14) • FGFR3 expression • SDC1 positive
|
bortezomib
25d
Location of the t(4;14) Translocation Breakpoint Identifies a Subset of Newly-Diagnosed Multiple Myeloma Patients with Poor Prognosis (ASH 2021)
From a large genomic dataset, we were able to discover and validate a clear association between the translocation breakpoints and survival outcome in t(4:14) ndMM patients. While prospective validation is needed before clinical application of our finding, molecular identification of high-risk t(4;14) patients using DNA breakpoint location may enable proper risk classification for this patient group at diagnosis, and would provide improved opportunities for risk-adjusted therapy and identification of a therapeutic target for this high-risk subpopulation. Ongoing work on mutation s, copy number, and differential gene expression analyses between translocation breakpoint sub-groups and will be presented.
Clinical
|
FGFR3 (Fibroblast growth factor receptor 3) • IGH (Immunoglobulin Heavy Locus)
|
Chr t(4;14) • FGFR3 expression
2ms
Tumor cell- intrinsic expression of FGFR3 drives anti-PDL-1 immunotherapy resistance in a murine bladder cancer model (SITC 2021)
The mechanism of resistance was not dependent on receptor kinase activity. Further studies are ongoing to determine the biochemical mechanisms of FGFR3-mediated immunotherapy resistance in bladder cancer.
Preclinical • PD(L)-1 Biomarker • IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • CD8 (cluster of differentiation 8)
|
FGFR3 mutation • FGFR3 G370C • FGFR3 expression • FGFR3 K508M
2ms
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma. (PubMed, Int J Mol Sci)
p53 expression may be considered as a prognostic factor for the anti-PD-L1 treatment efficacy of low-grade high-PD-L1-positive GATA3(-)/CR5/6(-)-relapsed noninvasive bladder cancer.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • GATA3 (GATA binding protein 3)
|
PD-L1 expression • TP53 mutation • FGFR3 mutation • TP53 expression • FGFR3 expression
3ms
[VIRTUAL] Single Cell Multi-Omic Analysis And Immune Cell Type Profi ling Of Multiple Myeloma With t(4;14) (SOHO 2021)
We present the first application of single cell multi-omics immune profiling in high-risk MM. Our results suggest that t(4;14) MM is a molecularly heterogeneous disease. That heterogeneity, coupled with our small sample size may explain the lack of correlation between gene or protein expression with clinical outcomes.
FGFR3 (Fibroblast growth factor receptor 3)
|
Chr t(4;14) • FGFR3 expression
3ms
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. (PubMed, Cancer Manag Res)
In univariable analysis, the prognostic effect of FGFR3 and CDKN2A was observed primarily in patients demonstrating high expression of KRT5 or KRT20, whereas high FGFR3 expression was associated with significantly reduced RFS, irrespective of instillation therapy. Stage T1 NMIBC patients with high FGFR3 expression show shorter RFS but better OS than patients with low FGFR3 expression.
Clinical • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin-dependent kinase inhibitor 2A) • KRT5 (Keratin 5) • KRT20 (Keratin 20)
|
CDKN2A negative • FGFR3 expression • CDKN2A expression
3ms
[VIRTUAL] Oncogenic chaperoning of Hsp90 in glioma with FGFR3-TACC3 (EANO 2021)
The experimental group was administered with temozolomide (5mg/kg/day) by oral gavage, Hsp90 inhibitor Onalespib (30mg/kg/day) by tail vein injection or the combination of the two for indicated days. F3-T3 is a strong Hsp90 client that shows strong addiction to the Hsp90-Cdc37 chaperone system. Combination therapy with Hsp90 inhibitor overcomes the TMZ resistance conferred by F3-T3.
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
FGFR3 fusion • FGFR3 expression
|
temozolomide • onalespib (AT13387)
4ms
Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment. (PubMed, Aging (Albany NY))
Targetable mutations were mainly detected in BLCA, and S249C, Y373C, G370C, and R248C were hotspot mutations that could be targeted by an FDA approved erdafitinib...FGFG3 abnormal expression and alterations exhibited clinical correlations with patient prognosis in several tumors. This work exhibited the full alteration spectrum of FGFR3 and indicated several new clues for their application as potential therapeutic targets and prognostic indicators.
Clinical • Journal • Pan tumor
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 expression
|
Balversa (erdafitinib)
5ms
Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer undergoing checkpoint inhibitor therapy. (PubMed, Urology)
Assessment of FGFR mRNA expression identified a high-risk subgroup of patients with mUCa. These patients showing overexpression of FGFR3 mRNA were found to have unfavorable DSS after CPI treatment. Using this approach may be suitable for identifying a patient population with poor response to CPI treatment, which may benefit from early FGFR inhibition.
Journal • Checkpoint inhibition
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
FGFR2 fusion • FGFR3 mutation • FGFR3 overexpression • FGFR3 fusion • FGFR1 expression • FGFR2b expression • FGFR3 expression • FGF3 overexpression • FGFR2 expression
6ms
[VIRTUAL] Gene expression profiling of hypoxia in bladder cancer cell lines (EACR 2021)
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
6ms
[VIRTUAL] Gene expression profiling of hypoxia in bladder cancer cell lines (EACR 2021)
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
6ms
[VIRTUAL] Gene expression profiling of hypoxia in bladder cancer cell lines (EACR 2021)
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
6ms
[VIRTUAL] Gene expression profiling of hypoxia in bladder cancer cell lines (EACR 2021)
Conclusion A 24-gene bladder cancer specific hypoxia signature is sensitive to changing oxygen levels in vitro . Increasing signatures scores in response to hypoxia is more consistent than the variable responses seen in the expression of genes associated with bladder cancer subtypes.
Preclinical
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • CA9 (Carbonic anhydrase 9)
|
HER-2 expression • EGFR expression • FGFR3 expression • CA9 expression
7ms
[VIRTUAL] SINGLE CELL MULTI-OMIC ANALYSIS AND IMMUNE CELL TYPE PROFILING OF MULTIPLE MYELOMA WITH T(4;14). (EHA 2021)
We propose that t(4;14) MM is a genomically and immunologically heterogeneous disease. Single cell analysis of larger cohorts is required to build on our findings.
IO biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • CRBN (Cereblon) • CD14 • SDC1 (Syndecan 1) • CTAG2 (Cancer/testis antigen 2)
|
Chr t(4;14) • FGFR3 expression • SDC1 positive
7ms
Expression Profile of Fibroblast Growth Factor Receptors, Keratinocyte Differentiation Markers, and Epithelial Mesenchymal Transition-Related Genes in Actinic Keratosis: A Possible Predictive Factor for Malignant Progression? (PubMed, Biology (Basel))
In conclusion, our data point on the identification of molecular markers predictive for AK rapid progression through the "differentiated" pathway. Our results also represent an important step that, in future, will help to clarify the molecular mechanisms underlying FGFR signaling deregulation in epithelial tissues during the switch from the pre-neoplastic to the oncogenic malignant phenotype.
Journal
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF2 (Fibroblast Growth Factor 2) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
FGFR3 expression
7ms
[VIRTUAL] Association of FGFR alterations with FGFR 1-4 gene expression in TUR biopsies and matched NMP22 urine levels in early bladder cancer of the prospective real world clinico-pathological register trial: BRIDGister. (ASCO 2021)
In early bladder cancer FGFR3 alterations are tightly associated with a characteristic FGFR mRNA signature . Mutation/Fusion of FGFR3 results in high FGFR3 but low FGFR1 and FGFR4 mRNA expression, which might be i.a . relevant for the response to FGFR inhibition and important to predict outcome of FGFR inhibitors .
Clinical • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR4 (Fibroblast growth factor receptor 4) • KRT5 (Keratin 5) • KRT20 (Keratin 20)
|
FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR4 expression
7ms
[VIRTUAL] Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study. (ASCO 2021)
First-line treatment with the RP2D of R+A achieved favorable clinical efficacy and tolerability in pts with cisplatin-ineligible, metastatic UC characterized by high FGFR1/3 mRNA expression and generally low/negative PD-L1 expression . Encouraging efficacy was observed regardless of PD-L1 expression or FGFR3 mutation status, warranting future investigation.
Combination therapy • P1/2 data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative • FGFR3 mutation • FGFR3 overexpression • FGFR fusion • FGFR1 expression • FGFR3 expression • FGF3 overexpression
|
cisplatin • Tecentriq (atezolizumab) • rogaratinib (BAY1163877)
9ms
The Clinicopathological Characteristics of Muscle-Invasive Bladder Recurrence in Upper Tract Urothelial Carcinoma. (PubMed, Cancer Sci)
In conclusion, our study demonstrated that UTUC patients who develop MIBC recurrence after RNU exhibit the clinical characteristics of subsequent IVR more than those of primary UTUC. Of note, MIBC subsequent to UTUC may have favorable outcomes, probably due to the different molecular biological background compared from primary MIBC.
Clinical • Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3)
|
TP53 expression • FGFR3 expression
9ms
[VIRTUAL] FGFR3 and eIF4E are overexpressed and interact with PRMT5 and KRAS in CRC (AACR 2021)
This significant observation can be therapeutically utilized towards developing new effective treatments for KRAS mutant CRC patients. Further analysis is currently in progress to verify the proposed molecular mechanism outlining how eIF4E and FGFR3 interact with PRMT5 and KRAS in CRC.
KRAS (KRAS proto-oncogene GTPase) • FGFR3 (Fibroblast growth factor receptor 3) • PRMT5 (Protein Arginine Methyltransferase 5)
|
KRAS mutation • FGFR3 overexpression • FGFR3 expression • FGF3 overexpression
9ms
Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma. (PubMed, PLoS One)
Our results suggest that high FGFR3 expression is associated with p16 negative status and mp53 expression in OPSCC and correlates with a worse clinical outcome. The biological relationship between FGFR3 and mp53 in OPSCC deserves further investigation.
Journal
|
TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
TP53 mutation • FGFR3 mutation • TP53 expression • CDKN2A negative • FGFR3 expression
11ms
The Expression and Prognostic Value of FGF2, FGFR3, and FGFBP1 in Esophageal Squamous Cell Carcinoma. (PubMed, Anal Cell Pathol (Amst))
The FGF2-FGFR3 axis may be a new direction of targeted therapy for esophageal squamous cell carcinoma. FGF2 and FGFR3 may be used as prognostic markers of esophageal squamous cell carcinoma.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGF2 (Fibroblast Growth Factor 2)
|
FGFR3 expression
1year
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma. (PubMed, Life (Basel))
tumor grade in association with PD-L1 and FGFR3 expression can be considered as a complex predictor for primary luminal NMIBC progression.
Journal • PD(L)-1 Biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR3 (Fibroblast growth factor receptor 3)
|
PD-L1 expression • PD-L1 overexpression • FGFR3 mutation • FGFR3 expression
1year
Circ_0061825 Acts as a miR-593-3p Sponge to Promote Breast Cancer Progression by Regulating FGFR3 Expression. (PubMed, Cancer Manag Res)
Circ_0061825 was characterized using ribonuclease (RNase) R digestion, actinomycin D and subcellular fractionation assays...Moreover, miR-593-3p overexpression hindered BC cell malignant progression in vitro by down-regulating FGFR3. Our current work provided evidence that circ_0061825, an up-regulated circRNA in BC, regulated BC malignant progression at least in part through targeting the miR-593-3p/FGFR3 axis, illuminating a novel therapeutic target for BC management.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 expression
|
dactinomycin
1year
FGFR3 signaling and function in triple negative breast cancer. (PubMed, Cell Commun Signal)
These results indicate that targeting FGFR3 may represent a therapeutic option for TNBC, but only for patients with oncogenic FGFR3 alterations, such as the FGFR3-TACC3 fusion. Video abstract.
Journal • PARP Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3) • FRS2 (Fibroblast Growth Factor Receptor Substrate 2)
|
FGFR3 mutation • FGFR3 fusion • FGFR3 expression
1year
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer (clinicaltrials.gov)
P1, N=20, Recruiting, M.D. Anderson Cancer Center | Phase classification: P1/2 --> P1
Clinical • Phase classification
|
FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 expression
|
Truseltiq (infigratinib)
over1year
[VIRTUAL] Genotyping of urinary bladder carcinomas for up-regulated EGFR , PIK3CA , FGFR3 and CDKN2A to determine the potential for targeted therapy (ESHG 2020)
The overexpression of the EGFR and PIK3CA was not found to be related to tested mutations and so far these two molecules are not convenient for bladder cancer targeted therapy. On the other hand the overexpression of FGFR3 and CDKN2A could be due to detected mutations.
EGFR (Epidermal growth factor receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin-dependent kinase inhibitor 2A)
|
PIK3CA mutation • EGFR overexpression • FGFR3 mutation • CDKN2A mutation • FGFR3 S249C • FGFR3 overexpression • FGFR3 Y375C • FGFR3 expression • PIK3CA overexpression
over1year
Identification of Differential Tumor Subtypes of T1 Bladder Cancer. (PubMed, Eur Urol)
PATIENT SUMMARY: We identified and characterized expression subtypes of high-grade stage T1 bladder cancer that are biologically heterogeneous and have variable responses to bacillus Calmette-Guérin treatment. We validated the subtypes and describe a single-patient classifier.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • E2F1 (E2F transcription factor 1)
|
MYC expression • FGFR3 expression
over1year
Clinical • P2 data • Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGF (Fibroblast Growth Factor)
|
HER-2 overexpression • FGFR3 overexpression • FGFR3 expression
|
Herceptin (trastuzumab) • Pemazyre (pemigatinib) • dexloxiglumide (CR2017)
over1year
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?. (PubMed, Eur Urol)
In this report, we found that these FGFR3 mutations were associated with favorable features and prognosis of bladder cancer compared with patients with FGFR3 overexpressed tumors only. As a consequence, patients with FGFR3 mutant tumors would be more likely to benefit from anti-FGFR3 therapy than patients with FGFR3 protein overexpression only.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
TP53 mutation • FGFR3 mutation • FGFR3 overexpression • FGFR3 expression
over1year
CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis. (PubMed, Aging (Albany NY))
Mechanistically, circFGFR3 upregulates E2F1 expression by sponging miR-29a-3p, and the overexpression of E2F1 or the suppression of miR-29a-3p induces OC cell EMT. Therefore, circFGFR3 serves as a promoter of OC by inducing OC cell EMT via the miR-29a-3p/E2F1 axis and circFGFR3 may be a prognostic biomarker for OC patients.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • E2F1 (E2F transcription factor 1)
|
FGFR3 expression
over1year
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. (PubMed, Eur Urol Oncol)
We did not find any robust association, mainly when analyzing the landscape of alterations defining tumors with higher biological FGFR activity. Overall, FGFR3 activity and gene alterations did not provide sufficiently robust data to exclude patients whose tumors harbor these alterations from neoadjuvant immunotherapy trials.
Clinical • Journal • PD(L)-1 Biomarker
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor) • FGF (Fibroblast Growth Factor)
|
FGFR3 mutation • FGFR3 fusion • FGFR3 expression
|
Keytruda (pembrolizumab)
over1year
[VIRTUAL] Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first an second line setting (AUA 2020)
The assessment of FGFR mRNA by standardized RT-qPCR identified a high risk UCB patient cohort, which does have inferior disease specific survival despite IO treatment and does overexpress FGFR3 mRNA. The assessment of FGFR mRNA levels by using this standardized, locally applicable FGFR testing could identify an FGFR inhibitor target population with poor response to IO treatment which is twice the size as currently detected by FGFR genomic alterations alone. Source of Funding: Janssen, Research & Development, LLC, USA
Clinical • PD(L)-1 Biomarker • IO biomarker
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR3 expression • FGFR expression
over1year
[VIRTUAL] Alternative format bispecific antibodies targeting multiple oncogenic FGFR3 mutations in bladder cancer through different mechanisms (AACR-II 2020)
Interestingly, different activities were observed in antibody-induced receptor degradation indicating that APLP2 and CD63 regulate FGFR3 trafficking via distinct mechanisms. FGFR3xAPLP2 AF bispecifics enhanced receptor degradation compared to parental FGFR3 antibody, while FGFR3xCD63 AF bispecifics increased growth inhibition without receptor degradation.Our proof-of-concept case study suggests that AF bispecific antibodies can be used as a single novel modality to offer more potent inhibition against diverse mechanisms of oncogenic receptor activation.
HER-2 (Human epidermal growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • TACC3 (Transforming acidic coiled-coil containing protein 3)
|
FGFR3 mutation • FGFR3 S249C • FGFR3 Y373C • FGFR3 fusion • FGFR3 G370C • FGFR3 R248C • FGFR3 expression
over1year
Interaction of FGF9 with FGFR3-IIIb/IIIc, a putative driver of growth and aggressive behavior of hepatocellular carcinoma. (PubMed, Liver Int)
FGF9 acts via FGFR3-IIIb/IIIc to enhance growth and aggressiveness of HCC cells. Accordingly, blockade of the FGF9-FGFR3-IIIb/IIIc axis may be an efficient therapeutic option for HCC patients.
Journal
|
FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGF (Fibroblast Growth Factor)
|
FGFR3 expression
|
Truseltiq (infigratinib)
over1year
[VIRTUAL] Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting (EAU-I 2020)
The assessment of FGFR mRNA by standardized RT-qPCR identified a high risk UCB patient cohort, which does have inferior disease specific survival despite IO treatment and does over express FGFR3 mRNA. The assessment of FGFR mRNA levels by using this standardized, locally applicable FGFR testing could identify an FGFR inhibitor target population with poor response to IO treatment which is twice the size as currently detected by FGFR genomic alterations alone.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR (Fibroblast Growth Factor Receptor)
|
PD-L1 expression • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 overexpression • FGFR3 fusion • FGFR3 expression • FGFR expression
over1year
[VIRTUAL] FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. (ASCO 2020)
This data suggests that while FGFR1-3 genes are overall expressed in CRC and lung, some cases may have significantly high expression of FGFR1-3 and perhaps these cases should be singled out for treatment with FGFR inhibitors. Furthermore, NGS testing for mutations significantly more efficient and can detect significant number of mutations that can be missed if PCR-based testing is used. NGS testing of DNA and RNA is the most appropriate testing for abnormalities in FGFR1-4.
Next-generation sequencing
|
FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3) • FGFR1 (Fibroblast growth factor receptor 1) • FGFR (Fibroblast Growth Factor Receptor) • FGFR4 (Fibroblast growth factor receptor 4) • FGF (Fibroblast Growth Factor)
|
FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR3 mutation • FGFR3 fusion • FGFR1 expression • FGFR1 fusion • FGFR3 expression • FGFR expression • FGFR4 expression